PDS Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	26.2	41.69	56.56	73.82	65.24	28.84
Cash & Short-Term Investments	26.2	41.69	56.56	73.82	65.24	28.84
Cash Growth	-47.34%	-26.29%	-23.38%	13.15%	126.23%	137.13%
Other Current Assets	1.69	3.36	2.49	2.66	1.6	1.5
Total Current Assets	27.89	45.05	59.06	76.48	66.84	30.34
Net Property, Plant & Equipment	0.26	0.3	0.34	0.53	0.36	0.55
Other Long-Term Assets	6.55	-	-	-	-	-
Total Assets	34.71	45.36	59.39	77.01	67.2	30.89
Accounts Payable	5.18	1.68	6.98	1.22	1.31	1.42
Accrued Expenses	2.1	2.84	2.42	8.31	2.19	1.74
Short-Term Debt	6	12.5	4.17	-	-	-
Current Portion of Leases	0.04	0.06	0.06	0.29	0.26	0.12
Total Current Liabilities	13.33	17.09	13.63	9.82	3.76	3.27
Long-Term Debt	11.89	9.2	19.51	23.02	-	-
Long-Term Leases	0.03	0.06	0.12	0.16	0.23	0.49
Total Long-Term Liabilities	11.92	9.27	19.63	23.18	0.23	0.49
Total Liabilities	25.25	26.35	33.26	33.01	3.99	3.76
Common Stock	0.02	0.01	0.01	0.01	0.01	0.01
Additional Paid-in Capital	218.48	201.1	170.62	145.55	123.9	70.91
Retained Earnings	-209.04	-182.11	-144.5	-101.56	-60.7	-43.79
Shareholders' Equity	9.45	19	26.13	44	63.21	27.13
Total Liabilities & Equity	34.71	45.36	59.39	77.01	67.2	30.89
Total Debt	17.97	21.83	23.85	23.47	0.49	0.61
Net Cash (Debt)	8.23	19.86	32.71	50.35	64.75	28.23
Net Cash Growth	-58.55%	-39.28%	-35.03%	-22.25%	129.38%	132.12%
Net Cash Per Share	0.19	0.55	1.06	1.76	2.53	1.69
Book Value	9.45	19	26.13	44	63.21	27.13
Book Value Per Share	0.22	0.52	0.84	1.54	2.47	1.62
Tangible Book Value	9.45	19	26.13	44	63.21	27.13
Tangible Book Value Per Share	0.22	0.52	0.84	1.54	2.47	1.62

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q